Vatelizumab Terminated Phase 2 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02306811Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
NCT02222948Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis